Skip to main content

Advertisement

Table 2 Prevalence and persistence in use of psychotropic drugs

From: Prevalence and persistent use of psychotropic drugs in older adults receiving domiciliary care at baseline

  Prevalence n (%)
A1 A2 A3
All D/nD All D/nD All D/nD
(N = 1001) (N = 415/586) (N = 599) (N = 304/295) (N = 453) (N = 227/226)
Psychotropic drug use
Antipsychotics (AP) 36 (3.6) 24/12 (5.8/2.0)** 28 (4.7) 22/6 (7.2/2.0)** 30 (6.6) 26/4 (11.5/1.8)***
 Traditional AP 31 (3.1) 19/12 (4.6/2.0)* 23 (3.8) 17/6 (5.6/2.0)* 23 (5.1) 19/4 (8.4/1.8)**
 Atypical AP 5 (0.5) 5/0 (1.2/0) 6 (1.0) 6/0 (2.0/0) 8 (1.8) 8/0 (3.5/0)
Antidepressants 155 (15.5) 82/73 (19.8/12.5)** 121 (20.2) 80/41 (26.3/13.9)*** 101 (22.3) 70/31 (30.8/13.7)***
Anxiolytics 86 (8.6) 43/43 (10.4/7.3) 71 (11.9) 48/23 (15.8/7.8)** 53 (11.7) 35/18 (15.4/8.0)*
Sedatives 221 (22.1) 103/118 (24.8/20.1) 128 (21.4) 78/50 (25.7/16.9)* 103 (22.7) 59/44 (26.0/19.5)
Anti-dementia drugs 57 (5.7) 53/4 (12.8/0.7)*** 60 (10.0) 57/3 (18.8/1.0)*** 34 (7.5) 31/3 (13.7/1.3)***
Any PTD 403 (40.3) 208/195 (50.1/33.3)*** 272 (45.4) 178/94 (58.6/31.9)*** 210 (46.4) 132/78 (58.1/34.5)***
  Persistence n (%)
A1-A2 A2-A3
All D/nD All D/nD
Psychotropic drug use
Antipsychotics (AP) 17 (63.0)a 12/5 (63.2/62.5) 13 (65.0)a 10/3 (62.5/75.0)
 Traditional AP 13 (54.2) 8/5 (50.0/62.5) 11 (64.7) 8/3 (61.5/75.0)
 Atypical AP 3 (100) 3/0 (100/0) 1 (25.0) 1/0 (25.0/0)
Antidepressants 83 (82.2) 45/38 (83.3/80.9) 69 (82.1) 41/28 (80.4/84.8)
Anxiolytics 29 (63.0) 17/12 (70.8/54.5) 22 (57.9) 14/8 (53.8/66.7)
Sedatives 77 (66.4) 37/40 (68.5/64.5) 52 (67.5) 27/25 (71.1/64.1)
Anti-dementia drugs 26 (74.3) 24/2 (75.0/66.7) 22 (66.7) 20/2 (64.5/100)
Any PTD 191 (81.3) 106/85 (86.9/75.2)* 142 (83.5) 85/57 (85.9/80.3)
  1. A1: Assessment 1, at baseline
  2. A2: Assessment 2, 18 months after baseline
  3. A3: Assessment 3, 36 months after baseline
  4. D Dementia, nD No dementia, PTD Psychotropic drugs
  5. * p < 0.05; ** p < 0.01; *** p < 0.001; p-values were calculated by generalized linear mixed model adjusting for municipality level if present
  6. aOne participant changed between traditional AP and atypical AP between assessments, which is why the numbers of persistent users of traditional AP plus persistent users of atypical AP does not equal persistent users of antipsychotics. This is the case for A1-A2 and A2-A3